Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer

Clin Genitourin Cancer. 2019 Oct;17(5):e1069-e1079. doi: 10.1016/j.clgc.2019.06.015. Epub 2019 Jul 2.

Abstract

Background: Muscle-invasive bladder cancer (MIBC) may be managed with radical cystectomy (RC) or chemoradiotherapy (CRT). Because patient selection for RC is important to avoid treatment-related mortality, this study addressed a knowledge gap by quantifying short-term mortality with both approaches, as well as predictors thereof.

Materials and methods: The National Cancer Database was queried (2004-2014) for clinically staged T2-4aN0M0 MIBC that received either CRT or RC. Statistics included cumulative incidence comparisons of 30- and 90-day mortality between patients treated with either CRT or RC and Cox regression to evaluate predictors thereof.

Results: Of 16,658 patients, 15,208 (91.3%) underwent RC and 1450 (8.7%) CRT. Crude rates of post-treatment mortality at 30 days were 2.7% versus 0.6% (P < .001) and at 90 days were 7.5% versus 4.5% (P = .017) for patients treated with RC and CRT, respectively. When stratifying by age, worse 30- and 90-day mortality with RC was observed for patients aged ≥ 76 years.

Conclusions: This study describes 30- and 90-day mortality following RC versus CRT. Both approaches yield statistically similar treatment-related mortality rates in patients ≤ 75 years of age; however, worse post-treatment mortality was observed with use of RC in patients ≥ 76 years of age. These results may be utilized to better inform shared decision-making between patients and providers when weighing both RC and CRT for MIBC.

Keywords: Bladder cancer; Chemoradiation; Cystectomy; Geriatric oncology; Organ preservation therapy.

Publication types

  • Comparative Study

MeSH terms

  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy / methods*
  • Cystectomy / methods*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Regression Analysis
  • Survival Analysis
  • Treatment Outcome
  • Urinary Bladder Neoplasms / mortality*
  • Urinary Bladder Neoplasms / therapy*